Offering HIV prophylaxis to people who have been sexually assaulted: 16 Months' experience in a sexual assault service

CMAJ. Canadian Medical Association Journal

Volumn 162, Issue 5, 2000, Pages 641-645

  Wiebe, Ellen R ^a   Comay, Susan E ^a   McGregor, Margaret ^b   Ducceschi, Sylvia ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CHEMOPROPHYLAXIS; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OUTCOMES RESEARCH; PATIENT COMPLIANCE; RISK ASSESSMENT; SEXUAL CRIME; VICTIM;

EID: 0034615588     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood -France, United Kingdom, and United States, January 1988-August 1994. MMiVR Morh Mortal Wkly Rep 1995;44:929-33.
2. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. US Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997;337:1485-90.
3. US Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMRW Marb Mortal inly Rep 1998;47 (RR-1):1-111.
4. Kirkham CM, Lobb DJ. The British Columbia Positive Women's Survey: a detailed profile of 110 HIV-infected women. CMAJ 1998;158(3):317-23.
5. Lopez-Varela M, Garcia-Rodriguez J, Martina-Zapico R. Low risk of HIV transmission in rape victims. Eur J Clin Aficrv HoI Infect Dis 1994;13:622.
6. Ledray LE. The sexual assault examination: overview and lessons learned in one program. J Emerg Nurs 1992;18:223-30.
7. Gostin LO, Lazzarini Z, Alexander D, Brandt AM, Mayer KH, Silverman DC. HIV testing, counseling, and prophylaxis after sexual assault. JAMA 1994;271:1436-44.
8. Albert J, Wahlberg J, Leitner T, Escanilla D, Uhlen M. Analysis of a rape case by direct sequencing of the human immunodeficiency virus type l pol and gag genes. J Virol 1994;68:5918-24.
9. Claydon E, Murphy S, Osbome EAI, Kitchen V, Smith JR, Harris JR. Rape and HIV. htJSTDAIDS 1991;2:200-1.
10. Padian NS, Shiboski SC, Glass SO, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results from a ten-year study. AmJEpidemol 1997;146:350-7.
11. DeGrurtola V, Seage GR III, Mayer KH, Horsburgh CR Jr. Infectiousness of HIV between male homosexual partners.J Clin Epidemiol 1989;42:849-56.
12. Royce R, Sena A, Gates WJ, Cohen M. Sexual transmission of HIV. NEnglJ AW1997;336:1072-8.
13. Kapiga S, Shao J, Lwihula G, Hunter D. Risk factors for HIV infection among women in Dar-es-Salaam, Tanzania. J Acquir Immune DeficSjndr 1994;7:301-9.
14. Annual report. Vancouver: EC Women's Hospital-Vancouver General Hospital Sexual Assault Service; 1998.
15. Slaughter L, Brown CRV, Crowley S, Peck R. Patterns of genital injury in female sexual assault victims. Am J Obstet Gynecol I997;176:609-16.
16. Lauber AA, Souma SM. Use of toluidine blue for documentation of traumatic intercourse. Obstet Gynecol 1982;60:644-8.
17. Jenny C, Hooton TM, Bowers A, Copass MK, Krieger JN, Hillier SL, et al. Sexually transmitted diseases in victims of rape. N Engl J AIeJ 1990;322:713-6.
18. Hogg RS, Strathdee SA, Craib KJ, O'Shaughnessy MV, Montaner JS, Schechter AIT. Alodelling the impact of HIV disease on mortality in gay and bisexual men. IntJ Epidemiol 1997;26:657-61.
19. FitzGerald JAI, Patrick DM, Strathdee S, Rekart Al, Elwood RK, Schechter AIT, et al. Use of incentives to increase compliance for TB screening in a population of intravenous drug users. Vancouver Injection Drug Use Study Group. IntJTuberc Lung Dis 1999;3:153-5.
20. Lai C, Beardsell A, Yip B, Hogg R, AIcLeod A. Utilization and adherence of a population-based post-exposure prophylaxis program. Can J Infect Da Suppl B 1999;IO:28B.
21. Alellors JW, Kingsley LA, Rinaldo CR Jr, Todd JA, Hoo BS, Kokka RP, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconveraon. Ann Intern Med 1995;122:573-9.
22. Wei X, Ghosh SO, Taylor AIE. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-22.
23. Conway B, Rouleau D, O'Shaughnessy AIV, Montaner JSG. Acute HIV infection -a unique opportunity for intervention. BCMedJ 1997;39:88-90.
24. Bamberger JD, Waldo CR, Gerberding JL, Katz AIH. Post-exposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault. AmJ Med 1999;106:323-6.
25. Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectiveness of post-exposure prophylaxis following sexual exposure to HWAIDS 1998;12:1067-78.
26. Albert T, Williams G. The economic burden ofHlV/AIDS in Canada [CPRN study no H-02J. Canadian Policy Research Networks; 1998.
27. Wilkins R. Use of postal codes and addresses in the analysis of health data, y Health Rep 1993;5:157-77.
28. Postal code conversion ßle, Custom, 1991 Census. Ottawa: Geography Division, Statistics Canada; 1992. Cat no 92C0002.